The Council will facilitate the licensing and use of effective novel TB vaccines catalysing high-level alignment between funders, global agencies, governments and end users in identifying and overcoming barriers to TB vaccine development.

A few recent Campaign updates from Treatment Action Group and allies.
Contact david.branigan@treatmentactiongroup.org for more information on how to be part of the 1/4/6x24 Campaign.

Advocates urge Johnson & Johnson to correct its course and stop blocking entry of generic versions of bedaquiline into the global market and into countries.

Médecins Sans Frontières urges the Indian Patent Office to reject the secondary patent application filed by Johnson & Johnson to prevent the company from extending its monopoly on bedaquiline beyond the primary patent’s expiry in July 2023.

The World Health Organization releases updated guidelines and a supporting operational handbook on the treatment of drug-resistant TB featuring major improvements in treatment options for people with multidrug-resistant or rifampicin-resistant TB.

GFAN is selected to coordinate the Affected Communities and Civil Society Platform for the 2023 UN High-Level Meeting on TB. Applications are now being accepted for lead consultant(s) to support this work (Deadline: 5 January 2023).

Innovative TB Community Service Delivery during the COVID-19 Pandemic: Best Practices and Lessons Learned from Cambodia, India, Indonesia, and Kenya

The manual provides an overview of the recommended use of IGRAs as a class of in-vitro tests for the detection of TB infection and describes their performance, steps for use and implementation considerations.

A document summarizes the results of the WHO-commissioned full value proposition for new TB vaccines.

A report highlights that despite reaching US$1 billion in spending in 2021, funding for TB R&D is a mere fraction of what’s needed to achieve UN sustainable development goal of ending TB as a pandemic by 2030.